Flora Growth Corp. (FLGC)
NASDAQ: FLGC · Real-Time Price · USD
0.6080
-0.0420 (-6.46%)
Mar 31, 2025, 2:10 PM EDT - Market open

Company Description

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.

It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.

It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs.

In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.

The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Flora Growth Corp.
Flora Growth logo
Country United States
Founded 2019
IPO Date May 11, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 108
CEO Clifford Starke

Contact Details

Address:
3406 SW 26th Terrace, Suite C-1
Fort Lauderdale, Florida 33132
United States
Phone 954 842 4989
Website floragrowth.com

Stock Details

Ticker Symbol FLGC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001790169
CUSIP Number 339764102
ISIN Number CA3397642016
SIC Code 2834

Key Executives

Name Position
Clifford A. Starke Chief Executive Officer and Director
Dany Vaiman Chief Financial Officer
Samuel Dorf Esq. Executive Chairman of the Board
Dr. Manfred Ziegler Managing Director
Patrick Moloney Head of Product Development
Aaron Atin Corporate Secretary

Latest SEC Filings

Date Type Title
Mar 28, 2025 EFFECT Notice of Effectiveness
Mar 25, 2025 S-3/A [Amend] Registration statement under Securities Act of 1933
Mar 24, 2025 10-K Annual Report
Feb 28, 2025 8-K Current Report
Feb 24, 2025 S-3 Registration statement under Securities Act of 1933
Feb 5, 2025 8-K Current Report
Jan 21, 2025 SCHEDULE 13G Filing
Dec 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 17, 2024 8-K Current Report